Leiomyosarcoma laboratory tests

Leiomyosarcoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Leiomyosarcoma from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Leiomyosarcoma laboratory tests On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Leiomyosarcoma laboratory tests

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Leiomyosarcoma laboratory tests

CDC on Leiomyosarcoma laboratory tests

Leiomyosarcoma laboratory tests in the news

Blogs on Leiomyosarcoma laboratory tests

Directions to Hospitals Treating Leiomyosarcoma

Risk calculators and risk factors for Leiomyosarcoma laboratory tests

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief:  Nima Nasiri, M.D.[2]

## Overview:

[edit | edit source]

There are no specific laboratory findings associated with leiomyosarcoma, patients may have low hemoglobin and red blood cells on their complete blood count, immunohistochemistry markers can be positive but non-diagnostics.

## Lab test:

[edit | edit source]

* There are no specific laboratory findings associated with leiomyosarcoma.
* Elevated levels of CA-125 and LDH( isozymes) in women with uterine sarcoma, the usefulness of these markers are still being investigated.
* There are immunohistochemistry markers associated with sarcoma but it can be positive in any other soft tissue tumors, some of these markers are include:[1][2][3]
* Actin and desmin positive.
* Diffusely positive with calponin, h-caldesmon.
* Negative with S100, c-kit and CD34

## References

[edit | edit source]

1. ↑ R, Stramare; G, Orsatti (2016). "Imaging Features, Differential Diagnosis and Management of Leiomyosarcomas: Case Series and Review of the Literature". Journal of Cancer Science & Therapy. 08 (04). doi:10.4172/1948-5956.1000397. ISSN 1948-5956.
2. ↑ Goto A, Takeuchi S, Sugimura K, Maruo T (2002) Usefulness of Gd-DTPA contrast-enhanced dynamic MRI and serum determination of LDH and its isozymes in the differential diagnosis of leiomyosarcoma from degenerated leiomyoma of the uterus. Int J Gynecol Cancer 12 (4):354-61. PMID: 12144683
3. ↑ Hoskins PJ, Le N (2008) Preoperative tumor markers at diagnosis in women with malignant mixed müllerian tumors/carcinosarcoma of the uterus. Int J Gynecol Cancer 18 (6):1200-1. DOI:10.1111/j.1525-1438.2007.01187.x PMID: 18217961

Template:WikiDoc Sources